{"generic":"Efinaconazole","drugs":["Efinaconazole","Jublia"],"mono":{"0":{"id":"930984-s-0","title":"Generic Names","mono":"Efinaconazole"},"1":{"id":"930984-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930984-s-1-4","title":"Adult Dosing","mono":"<b>Onychomycosis due to dermatophyte, Toenails:<\/b> apply TOPICALLY to affected toenails once daily for 48 weeks; completely cover the toenail, including folds, bed, hyponychium, and undersurface of toenail plate with each application "},"1":{"id":"930984-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"930984-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Onychomycosis due to dermatophyte, Toenails<br\/>"}}},"3":{"id":"930984-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930984-s-3-9","title":"Contraindications","mono":"No specific contraindications or warnings have been identified.<br\/>"},{"id":"930984-s-3-10","title":"Precautions","mono":"No specific contraindications or warnings have been identified.<br\/>"},{"id":"930984-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930984-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930984-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Dermatitis, application site (2.2%), Ingrowing toenail (2.3%)<br\/>"},"6":{"id":"930984-s-6","title":"Drug Name Info","sub":{"0":{"id":"930984-s-6-17","title":"US Trade Names","mono":"Jublia<br\/>"},"2":{"id":"930984-s-6-19","title":"Class","mono":"<ul><li>Antifungal<\/li><li>Triazole<\/li><\/ul>"},"3":{"id":"930984-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930984-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930984-s-7","title":"Mechanism Of Action","mono":"Efinaconazole is an azole antifungal. Fungicidal activity of efinaconazole is via inhibition of fungal lanosterol 14 alfa-demethylase. Synthesis of ergosterol for fungal cell membranes is catalyzed by fungal lanosterol 14 alfa-demethylase.<br\/>"},"8":{"id":"930984-s-8","title":"Pharmacokinetics","sub":{"4":{"id":"930984-s-8-27","title":"Elimination Half Life","mono":"29.9 hours <br\/>"}}},"9":{"id":"930984-s-9","title":"Administration","mono":"<b>Topical<\/b><br\/><ul><li>topical use only; not for oral, ophthalmic, or intravaginal use<\/li><li>apply with the supplied integrated flow-through brush applicator to clean and dry toenail(s); after showering, bathing, or washing, allow at least 10 minutes before application<\/li><li>contents are flammable; avoid heat or flame; store bottle upright<\/li><\/ul>"},"10":{"id":"930984-s-10","title":"Monitoring","mono":"improvement in the signs and symptoms of onychomycosis may indicate efficacy<br\/>"},"11":{"id":"930984-s-11","title":"How Supplied","mono":"<b>Jublia<\/b><br\/>Topical Solution: 10 %<br\/>"},"13":{"id":"930984-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report persistent irritation at application site.<\/li><li>Advise patient to avoid use near heat or open flame since solution is flammable.<\/li><li>Side effects may include ingrown toenails, or application site dermatitis, vesicles, or pain.<\/li><li>Instruct patient to wait at least 10 minutes after showering, bathing, or washing before applying drug.<\/li><\/ul>"}}}